- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Olokizumab safe and effective for treatment of rheumatoid arthritis: BMJ
Russia: Treatment with Olokizumab (OKZ) was linked with considerable improvement in signs, symptoms, and physical function of rheumatoid arthritis, as shown in a study conducted by Evgeniy Nasonov and colleagues, with no obvious differences between the two regimens. The immunogenicity was found to be low. The findings of this study were published in the British Medical Journal: Annals of the Rheumatic Diseases on 5th July 2021.
There are now a variety of viable treatments for RA with various mechanisms of action; nevertheless, many patients with active RA fail to attain stated therapeutic goals, such as low disease activity or remission. The aim of this study was to assess the effectiveness and safety of olokizumab (OKZ) in patients with active rheumatoid arthritis who are receiving methotrexate therapy (MTX).
Patients were randomly assigned 1:1:1 to receive subcutaneously injected OKZ 64 mg once every 2 weeks, OKZ 64 mg once every 4 weeks, or placebo with MTX in this 24-week multicenter, placebo-controlled, double-blind trial. The proportion of patients attaining an American College of Rheumatology 20 percent (ACR20) response at week 12 was the main efficacy objective. The secondary objectives included the percentage of individuals who achieved a Disease Activity Score 28- joint count based on C reactive protein 3.2, a Health Assessment Questionnaire Disability Index at week 12, an ACR50 response, and a Clinical Disease Activity Index of 2.8 at week 24.
Key Findings:
o ACR20 responses were higher in the olokizumab groups — 63.6 percent in those treated every two weeks and 70.4 percent in those treated every four weeks — than in the placebo groups (25.9 percent).
o There were substantial differences in all secondary effectiveness objectives between the olokizumab and placebo groups.
o In terms of safety, more patients in the olokizumab groups experienced treatment-emergent severe adverse events than in the placebo arm, with infections being the most prevalent.
o According to the researchers, none of the individuals produced neutralizing anti-drug antibodies.
In conclusion, there is a positive response of olokizumab towards RA treatment, and the author further added, "OKZ was reasonably well-tolerated over a period of 24 weeks with no unexpected safety findings.".
Reference:
Nasonov, E., Fatenejad, S., Feist, E., Ivanova, M., Korneva, E., Krechikova, D. G., Maslyanskiy, A. L., Samsonov, M., Stoilov, R., Zonova, E. V., & Genovese, M. (2021). Olokizumab, a monoclonal antibody against interleukin 6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by methotrexate: efficacy and safety results of a randomised controlled phase III study. Annals of the Rheumatic Diseases, annrheumdis-2021-219876. https://doi.org/10.1136/annrheumdis-2021-219876
Medical Dialogues consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751